Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000766548 | SCV000526652 | likely benign | not provided | 2021-06-25 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 19847392) |
Eurofins Ntd Llc |
RCV000433645 | SCV000707710 | likely benign | not specified | 2017-04-28 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000433645 | SCV000711483 | benign | not specified | 2014-11-24 | criteria provided, single submitter | clinical testing | Glu868Lys in exon 22 of LARS2: This variant is not expected to have clinical sig nificance because it has been identified in 1.0% (42/4406) of African American c hromosomes from a broad population by the NHLBI Exome Sequencing Project (http:/ /evs.gs.washington.edu/EVS; dbSNP rs34965084). |
Labcorp Genetics |
RCV000766548 | SCV001099917 | likely benign | not provided | 2025-01-21 | criteria provided, single submitter | clinical testing | |
Al Jalila Children’s Genomics Center, |
RCV001731681 | SCV001984442 | likely benign | Perrault syndrome 4 | 2020-07-23 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000766548 | SCV004154334 | likely benign | not provided | 2022-09-01 | criteria provided, single submitter | clinical testing | LARS2: BP4, BS1 |
Breakthrough Genomics, |
RCV000766548 | SCV005260795 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003972637 | SCV004790306 | benign | LARS2-related disorder | 2019-09-04 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |